West Paces Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.89K | Buy |
+18
| New | +$3.44K | ﹤0.01% | 488 |
|
|
2025
Q2 | – | Sell |
-70
| Closed | -$9.58K | – | 243 |
|
|
2025
Q1 | $9.58K | Hold |
70
| – | – | ﹤0.01% | 351 |
|
|
2024
Q4 | $10.7K | Hold |
70
| – | – | ﹤0.01% | 344 |
|
|
2024
Q3 | $13.6K | Hold |
70
| – | – | ﹤0.01% | 324 |
|
|
2024
Q2 | $16.2K | Hold |
70
| – | – | ﹤0.01% | 308 |
|
|
2024
Q1 | $15.1K | Sell |
70
-1
| -1% | -$234 | ﹤0.01% | 330 |
|
|
2023
Q4 | $18.4K | Buy |
71
+1
| +1% | +$246 | 0.01% | 313 |
|
|
2023
Q3 | $18K | Hold |
70
| – | – | 0.01% | 304 |
|
|
2023
Q2 | $19.9K | Hold |
70
| – | – | 0.01% | 310 |
|
|
2023
Q1 | $19.5K | Hold |
70
| – | – | 0.01% | 313 |
|
|
2022
Q4 | $19.4K | Hold |
70
| – | – | 0.01% | 294 |
|
|
2022
Q3 | $18.7K | Hold |
70
| – | – | 0.01% | 289 |
|
|
2022
Q2 | $14.3K | Hold |
70
| – | – | ﹤0.01% | 333 |
|
|
2022
Q1 | $14.7K | Hold |
70
| – | – | ﹤0.01% | 342 |
|
|
2021
Q4 | $16.8K | Sell |
70
-20
| -22% | -$5.14K | 0.01% | 332 |
|
|
2021
Q3 | $25.5K | Sell |
90
-50
| -36% | -$16.4K | 0.01% | 264 |
|
|
2021
Q2 | $48.5K | Hold |
140
| – | – | 0.02% | 207 |
|
|
2021
Q1 | $39.2K | Buy |
140
+50
| +56% | +$13.5K | 0.02% | 213 |
|
|
2020
Q4 | $22K | Hold |
90
| – | – | 0.01% | 245 |
|
|
2020
Q3 | $25.5K | Hold |
90
| – | – | 0.01% | 222 |
|
|
2020
Q2 | $24.1K | Hold |
90
| – | – | 0.01% | 236 |
|
|
2020
Q1 | $28.5K | Sell |
90
-22
| -20% | -$6.68K | 0.02% | 208 |
|
|
2019
Q4 | $33.2K | Sell |
112
-1
| -0.9% | -$277 | 0.02% | 228 |
|
|
2019
Q3 | $26.3K | Sell |
113
-13
| -10% | -$3.03K | 0.02% | 233 |
|
|
2019
Q2 | $29.5K | Sell |
126
-4
| -3% | -$924 | 0.02% | 209 |
|
|
2019
Q1 | $30.7K | Hold |
130
| – | – | 0.02% | 208 |
|
|
2018
Q4 | $39.1K | Hold |
130
| – | – | 0.03% | 192 |
|
|
2018
Q3 | $45.9K | Hold |
130
| – | – | 0.03% | 182 |
|
|
2018
Q2 | $37.7K | Buy |
130
+4
| +3% | +$1.13K | 0.03% | 197 |
|
|
2018
Q1 | $34.5K | Hold |
126
| – | – | 0.03% | 202 |
|
|
2017
Q4 | $40.1K | Hold |
126
| – | – | 0.03% | 200 |
|
|
2017
Q3 | $39.5K | Hold |
126
| – | – | 0.03% | 192 |
|
|
2017
Q2 | $34.2K | Hold |
126
| – | – | 0.03% | 205 |
|
|
2017
Q1 | $34.5K | Hold |
126
| – | – | 0.03% | 199 |
|
|
2016
Q4 | $35.7K | Buy |
+126
| New | +$37.4K | 0.03% | 204 |
|
Other funds holding BIIB
West Paces Advisors's BIIB Position: Q2 2026 in Review
West Paces Advisors opened a new position in Biogen (BIIB) in Q2 2026: 18 shares worth $3.89K. The stake represents ﹤0.01% of the portfolio and ranks #488 among its holdings. This is a return to the name: West Paces Advisors previously reported a position in BIIB as recently as Q1 2025.
West Paces Advisors first reported a position in BIIB in Q4 2016 and has held it in 35 quarters since. The position peaked at $48.5K in Q2 2021. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- West Paces Advisors held 18 shares of Biogen worth $3.89K as of Q2 2026.
- Biogen was a new West Paces Advisors position in Q2 2026.
- Biogen made up ﹤0.01% of West Paces Advisors's portfolio in Q2 2026, its #488 holding.
- West Paces Advisors first reported a position in Biogen in Q4 2016 and has held it in 35 quarters since.
- West Paces Advisors's Biogen position peaked at $48.5K in Q2 2021.
- 1,041 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on West Paces Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.